Metastatic Colorectal Cancer - ADVANCED - E7208

E7208

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-RAS Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.